EP2903613 - PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF IRAK4 ACTIVITY [Right-click to bookmark this link] | |||
Former [2015/33] | INHIBITORS OF IRAK4 ACTIVITY | ||
[2017/20] | Status | No opposition filed within time limit Status updated on 28.09.2018 Database last updated on 03.09.2024 | |
Former | The patent has been granted Status updated on 20.10.2017 | ||
Former | Grant of patent is intended Status updated on 01.05.2017 | ||
Former | Examination is in progress Status updated on 25.11.2016 | Most recent event Tooltip | 17.07.2020 | Lapse of the patent in a contracting state New state(s): AL | published on 19.08.2020 [2020/34] | Applicant(s) | For all designated states Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway, NJ 07065-0907 / US | [2015/33] | Inventor(s) | 01 /
SEGANISH, Michael W. 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 02 /
HANISAK, Jennifer 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 03 /
LI, Guoqing 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 04 /
ZHANG, Rui 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 05 /
TANG, Haiqun 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | [2015/33] | Representative(s) | Jaap, David Robert, et al Merck Sharp & Dohme Corp. 120 Moorgate London, EC2M 6UR / GB | [N/P] |
Former [2017/47] | Jaap, David Robert, et al Merck Sharp & Dohme Corp. European Patent Department Hertford Road Hoddesdon, Hertfordshire EN11 9BU / GB | ||
Former [2015/33] | Buchan, Gavin MacNicol, et al Merck & Co., Inc. European Patent Department Hertford Road Hoddesdon, Hertfordshire EN11 9BU / GB | Application number, filing date | 13845052.3 | 03.10.2013 | [2015/33] | WO2013US63173 | Priority number, date | US201261710958P | 08.10.2012 Original published format: US 201261710958 P | [2015/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014058691 | Date: | 17.04.2014 | Language: | EN | [2014/16] | Type: | A1 Application with search report | No.: | EP2903613 | Date: | 12.08.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.04.2014 takes the place of the publication of the European patent application. | [2015/33] | Type: | B1 Patent specification | No.: | EP2903613 | Date: | 22.11.2017 | Language: | EN | [2017/47] | Search report(s) | International search report - published on: | US | 17.04.2014 | (Supplementary) European search report - dispatched on: | EP | 18.03.2016 | Classification | IPC: | A61K31/44, A61K31/415, C07D231/02 | [2015/33] | CPC: |
C07D409/14 (EP,US);
A61K31/4439 (EP,US);
A61K31/444 (EP,US);
A61K31/496 (EP,US);
A61K31/497 (EP,US);
A61K31/506 (EP,US);
A61K31/5377 (EP,US);
A61K45/06 (EP,US);
C07D401/12 (EP,US);
| C-Set: |
A61K31/4439, A61K2300/00 (US,EP);
A61K31/444, A61K2300/00 (EP,US);
A61K31/496, A61K2300/00 (US,EP);
A61K31/506, A61K2300/00 (EP,US); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/33] | Extension states | BA | 08.05.2015 | ME | 08.05.2015 | Title | German: | PYRAZOLDERIVATE ZUR VERWENDUNG ALS INHIBITOREN DER IRAK4-AKTIVITÄT | [2017/20] | English: | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF IRAK4 ACTIVITY | [2017/20] | French: | COMPOSÉS PYRAZOLIQUES UTILES EN TANT QU'INHIBITEURS D'ACTIVITÉ D'IRAK4 | [2017/20] |
Former [2015/33] | INHIBITOREN DER IRAK4-AKTIVITÄT | ||
Former [2015/33] | INHIBITORS OF IRAK4 ACTIVITY | ||
Former [2015/33] | INHIBITEURS D'ACTIVITÉ D'IRAK4 | Entry into regional phase | 08.05.2015 | National basic fee paid | 08.05.2015 | Search fee paid | 08.05.2015 | Designation fee(s) paid | 08.05.2015 | Examination fee paid | Examination procedure | 08.05.2015 | Examination requested [2015/33] | 07.10.2016 | Amendment by applicant (claims and/or description) | 24.11.2016 | Despatch of a communication from the examining division (Time limit: M04) | 31.03.2017 | Reply to a communication from the examining division | 02.05.2017 | Communication of intention to grant the patent | 05.09.2017 | Fee for grant paid | 05.09.2017 | Fee for publishing/printing paid | 05.09.2017 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 24.11.2016 | Opposition(s) | 23.08.2018 | No opposition filed within time limit [2018/44] | Fees paid | Renewal fee | 07.10.2015 | Renewal fee patent year 03 | 07.10.2016 | Renewal fee patent year 04 | 10.10.2017 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 03.10.2013 | AL | 22.11.2017 | AT | 22.11.2017 | CY | 22.11.2017 | CZ | 22.11.2017 | DK | 22.11.2017 | EE | 22.11.2017 | ES | 22.11.2017 | FI | 22.11.2017 | HR | 22.11.2017 | IT | 22.11.2017 | LT | 22.11.2017 | LV | 22.11.2017 | MC | 22.11.2017 | MK | 22.11.2017 | NL | 22.11.2017 | PL | 22.11.2017 | PT | 22.11.2017 | RO | 22.11.2017 | RS | 22.11.2017 | SE | 22.11.2017 | SI | 22.11.2017 | SK | 22.11.2017 | SM | 22.11.2017 | TR | 22.11.2017 | BG | 22.02.2018 | NO | 22.02.2018 | GR | 23.02.2018 | IS | 22.03.2018 | [2020/33] |
Former [2020/32] | HU | 03.10.2013 | |
AT | 22.11.2017 | ||
CY | 22.11.2017 | ||
CZ | 22.11.2017 | ||
DK | 22.11.2017 | ||
EE | 22.11.2017 | ||
ES | 22.11.2017 | ||
FI | 22.11.2017 | ||
HR | 22.11.2017 | ||
IT | 22.11.2017 | ||
LT | 22.11.2017 | ||
LV | 22.11.2017 | ||
MC | 22.11.2017 | ||
MK | 22.11.2017 | ||
NL | 22.11.2017 | ||
PL | 22.11.2017 | ||
PT | 22.11.2017 | ||
RO | 22.11.2017 | ||
RS | 22.11.2017 | ||
SE | 22.11.2017 | ||
SI | 22.11.2017 | ||
SK | 22.11.2017 | ||
SM | 22.11.2017 | ||
TR | 22.11.2017 | ||
BG | 22.02.2018 | ||
NO | 22.02.2018 | ||
GR | 23.02.2018 | ||
IS | 22.03.2018 | ||
Former [2020/31] | HU | 03.10.2013 | |
AT | 22.11.2017 | ||
CY | 22.11.2017 | ||
CZ | 22.11.2017 | ||
DK | 22.11.2017 | ||
EE | 22.11.2017 | ||
ES | 22.11.2017 | ||
FI | 22.11.2017 | ||
HR | 22.11.2017 | ||
IT | 22.11.2017 | ||
LT | 22.11.2017 | ||
LV | 22.11.2017 | ||
MC | 22.11.2017 | ||
MK | 22.11.2017 | ||
NL | 22.11.2017 | ||
PL | 22.11.2017 | ||
PT | 22.11.2017 | ||
RO | 22.11.2017 | ||
RS | 22.11.2017 | ||
SE | 22.11.2017 | ||
SI | 22.11.2017 | ||
SK | 22.11.2017 | ||
SM | 22.11.2017 | ||
TR | 22.11.2017 | ||
BG | 22.02.2018 | ||
NO | 22.02.2018 | ||
GR | 23.02.2018 | ||
Former [2020/28] | AT | 22.11.2017 | |
CY | 22.11.2017 | ||
CZ | 22.11.2017 | ||
DK | 22.11.2017 | ||
EE | 22.11.2017 | ||
ES | 22.11.2017 | ||
FI | 22.11.2017 | ||
HR | 22.11.2017 | ||
IT | 22.11.2017 | ||
LT | 22.11.2017 | ||
LV | 22.11.2017 | ||
MC | 22.11.2017 | ||
NL | 22.11.2017 | ||
PL | 22.11.2017 | ||
PT | 22.11.2017 | ||
RO | 22.11.2017 | ||
RS | 22.11.2017 | ||
SE | 22.11.2017 | ||
SI | 22.11.2017 | ||
SK | 22.11.2017 | ||
SM | 22.11.2017 | ||
TR | 22.11.2017 | ||
BG | 22.02.2018 | ||
NO | 22.02.2018 | ||
GR | 23.02.2018 | ||
Former [2020/16] | AT | 22.11.2017 | |
CY | 22.11.2017 | ||
CZ | 22.11.2017 | ||
DK | 22.11.2017 | ||
EE | 22.11.2017 | ||
ES | 22.11.2017 | ||
FI | 22.11.2017 | ||
HR | 22.11.2017 | ||
IT | 22.11.2017 | ||
LT | 22.11.2017 | ||
LV | 22.11.2017 | ||
MC | 22.11.2017 | ||
NL | 22.11.2017 | ||
PL | 22.11.2017 | ||
RO | 22.11.2017 | ||
RS | 22.11.2017 | ||
SE | 22.11.2017 | ||
SI | 22.11.2017 | ||
SK | 22.11.2017 | ||
SM | 22.11.2017 | ||
TR | 22.11.2017 | ||
BG | 22.02.2018 | ||
NO | 22.02.2018 | ||
GR | 23.02.2018 | ||
Former [2019/28] | AT | 22.11.2017 | |
CY | 22.11.2017 | ||
CZ | 22.11.2017 | ||
DK | 22.11.2017 | ||
EE | 22.11.2017 | ||
ES | 22.11.2017 | ||
FI | 22.11.2017 | ||
HR | 22.11.2017 | ||
IT | 22.11.2017 | ||
LT | 22.11.2017 | ||
LV | 22.11.2017 | ||
MC | 22.11.2017 | ||
NL | 22.11.2017 | ||
PL | 22.11.2017 | ||
RO | 22.11.2017 | ||
RS | 22.11.2017 | ||
SE | 22.11.2017 | ||
SI | 22.11.2017 | ||
SK | 22.11.2017 | ||
SM | 22.11.2017 | ||
BG | 22.02.2018 | ||
NO | 22.02.2018 | ||
GR | 23.02.2018 | ||
Former [2018/52] | AT | 22.11.2017 | |
CY | 22.11.2017 | ||
CZ | 22.11.2017 | ||
DK | 22.11.2017 | ||
EE | 22.11.2017 | ||
ES | 22.11.2017 | ||
FI | 22.11.2017 | ||
HR | 22.11.2017 | ||
IT | 22.11.2017 | ||
LT | 22.11.2017 | ||
LV | 22.11.2017 | ||
NL | 22.11.2017 | ||
PL | 22.11.2017 | ||
RO | 22.11.2017 | ||
RS | 22.11.2017 | ||
SE | 22.11.2017 | ||
SI | 22.11.2017 | ||
SK | 22.11.2017 | ||
SM | 22.11.2017 | ||
BG | 22.02.2018 | ||
NO | 22.02.2018 | ||
GR | 23.02.2018 | ||
Former [2018/40] | AT | 22.11.2017 | |
CY | 22.11.2017 | ||
CZ | 22.11.2017 | ||
DK | 22.11.2017 | ||
EE | 22.11.2017 | ||
ES | 22.11.2017 | ||
FI | 22.11.2017 | ||
HR | 22.11.2017 | ||
IT | 22.11.2017 | ||
LT | 22.11.2017 | ||
LV | 22.11.2017 | ||
NL | 22.11.2017 | ||
PL | 22.11.2017 | ||
RO | 22.11.2017 | ||
RS | 22.11.2017 | ||
SE | 22.11.2017 | ||
SK | 22.11.2017 | ||
SM | 22.11.2017 | ||
BG | 22.02.2018 | ||
NO | 22.02.2018 | ||
GR | 23.02.2018 | ||
Former [2018/39] | AT | 22.11.2017 | |
CY | 22.11.2017 | ||
CZ | 22.11.2017 | ||
DK | 22.11.2017 | ||
EE | 22.11.2017 | ||
ES | 22.11.2017 | ||
FI | 22.11.2017 | ||
HR | 22.11.2017 | ||
IT | 22.11.2017 | ||
LT | 22.11.2017 | ||
LV | 22.11.2017 | ||
NL | 22.11.2017 | ||
PL | 22.11.2017 | ||
RS | 22.11.2017 | ||
SE | 22.11.2017 | ||
SK | 22.11.2017 | ||
SM | 22.11.2017 | ||
BG | 22.02.2018 | ||
NO | 22.02.2018 | ||
GR | 23.02.2018 | ||
Former [2018/37] | AT | 22.11.2017 | |
CY | 22.11.2017 | ||
CZ | 22.11.2017 | ||
DK | 22.11.2017 | ||
EE | 22.11.2017 | ||
ES | 22.11.2017 | ||
FI | 22.11.2017 | ||
HR | 22.11.2017 | ||
LT | 22.11.2017 | ||
LV | 22.11.2017 | ||
NL | 22.11.2017 | ||
PL | 22.11.2017 | ||
RS | 22.11.2017 | ||
SE | 22.11.2017 | ||
SK | 22.11.2017 | ||
SM | 22.11.2017 | ||
BG | 22.02.2018 | ||
NO | 22.02.2018 | ||
GR | 23.02.2018 | ||
Former [2018/35] | AT | 22.11.2017 | |
CY | 22.11.2017 | ||
CZ | 22.11.2017 | ||
DK | 22.11.2017 | ||
EE | 22.11.2017 | ||
ES | 22.11.2017 | ||
FI | 22.11.2017 | ||
HR | 22.11.2017 | ||
LT | 22.11.2017 | ||
LV | 22.11.2017 | ||
NL | 22.11.2017 | ||
RS | 22.11.2017 | ||
SE | 22.11.2017 | ||
SK | 22.11.2017 | ||
BG | 22.02.2018 | ||
NO | 22.02.2018 | ||
GR | 23.02.2018 | ||
Former [2018/24] | AT | 22.11.2017 | |
ES | 22.11.2017 | ||
FI | 22.11.2017 | ||
HR | 22.11.2017 | ||
LT | 22.11.2017 | ||
LV | 22.11.2017 | ||
NL | 22.11.2017 | ||
RS | 22.11.2017 | ||
SE | 22.11.2017 | ||
BG | 22.02.2018 | ||
NO | 22.02.2018 | ||
GR | 23.02.2018 | ||
Former [2018/22] | ES | 22.11.2017 | |
FI | 22.11.2017 | ||
LT | 22.11.2017 | ||
NL | 22.11.2017 | ||
NO | 22.02.2018 | Documents cited: | Search | [A]US8148411 (BOTHE ULRICH [DE], et al) [A] 1-10 * column 7, line 55 - column 9, line 49; examples 1.10, 1.14, 1.16; claims 1, 5 *; | [A]WO2011043371 (ASTELLAS PHARMA INC [JP], et al) [A] 1-10 * several compounds of the description, for example compounds 20 (page 85), 25 (page 86), 36 and 38 (page 87), 20 (page 105), 157 (page 116), etc.;; claims 1, 7, 8 *; | [A]US2011306589 (BLEICHER KONRAD [DE], et al) [A] 1-10 * claims 1, 54 * | International search | [Y]US2012115861 (CALDERINI MICHEL [DE], et al); | [Y]US8148411 (BOTHE ULRICH [DE], et al); | [A]WO2012129258 (MERCK SHARP & DOHME [US], et al); | [YP]WO2013042137 (AURIGENE DISCOVERY TECH LTD [IN], et al) | [Y] - WANG, Z ET AL., "IRAK-4 Inhibitors for Inflammation.", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 9, no. 8, (2009), pages 724 - 737, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182414, (20140110), XP055067855 DOI: http://dx.doi.org/10.2174/156802609789044407 |